Friday, June 27, 2008

Fw: Separation and characterization of respirable amphibole fibers from Libby, Montana.



----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Thursday, June 26, 2008 10:12:42 PM
Subject: Separation and characterization of respirable amphibole fibers from Libby, Montana.

[1]Inhal Toxicol. 2008 Jun; 20(8): 733-40
Webber JS, Blake DJ, Ward TJ, Pfau JC

The vermiculite mine in Libby, Montana, was in operation for over 70 yr and was contaminated with asbestos-like amphibole fibers. The mining, processing, and shipping of this vermiculite led to significant fiber inhalation exposure throughout the community, and residents of Libby have developed numerous pulmonary diseases such as lung cancer and mesothelioma. The present study describes the separation of Libby 6-mix into respirable and nonrespirable size fractions by means of aqueous elutriation. The elutriator, designed to separate fibers with aerodynamic diameters smaller than 2.5 microm (respirable) from larger fibers, used an upward flow rate of 3.4 x 10(- 4) cm s(-1). The resultant respirable fraction constituted only 13% of the raw Libby 6-mix mass, and less than 2% of the fibers in the elutriated fraction had aerodynamic diameters exceeding 2.5 microm. Surface area of the elutriated fibers was 5.3 m(- 2) g(-1), compared to 0.53 m(-2) g(-1) for the raw fibers. There were no detectable differences in chemical composition between the larger and smaller fibers. Such harvesting of respirable fractions will allow toxicological studies to be conducted within a controlled laboratory setting, utilizing fiber sizes that may more accurately simulate historical exposure of Libby residents' lungs. Importantly, this work describes a method that allows the use of material enriched in more uniform respirable material than raw Libby 6-mix, making comparisons with other known fiber preparations more valid on a mass basis.



___
Source: http://www.hubmed.org/display.cgi?uids=18569095
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Immunophenotyping of serous carcinoma of the female genital tract.



----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Thursday, June 26, 2008 10:12:42 PM
Subject: Immunophenotyping of serous carcinoma of the female genital tract.

[1]Mod Pathol. 2008 Jun 20;
Nofech-Mozes S, Khalifa MA, Ismiil N, Saad RS, Hanna WM, Covens A, Ghorab Z

To update the data on the expression of 'mesothelioma markers' by serous carcinomas of various sites we have studied cases from ovary (n=56), endometrium (n=37), fallopian tube (n=6), primary peritoneum (n=5) and cervix (n=3) using a panel of antibodies (WT1, P53, estrogen receptors, HER2/neu, D2-40, cytokeratin 5/6 and E-cadherin). Ovarian carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 23.2 and 55.4% of cases, respectively. Endometrial carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 43.2 and 37.8% of cases, respectively. D2-40 staining pattern was predominantly focal; however, strong reactivity was identified in 16.2% of endometrial and 10.7% of ovarian carcinomas. HER2/neu oncoprotein overexpression was demonstrated in 7 of 37 (18.9%) uterine serous carcinomas. In contrast, all the serous carcinomas of the other sites were HER2/neu negative. The proportion of positive cases was significantly different in ovarian vs endometrial carcinomas regarding WT1 (P=0.0458), estrogen receptors (P

___
Source: http://www.hubmed.org/display.cgi?uids=18567994
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Phosphorylation and localization of protein-zero related (PZR) in cultured endothelial cells.



----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Thursday, June 26, 2008 10:12:42 PM
Subject: Phosphorylation and localization of protein-zero related (PZR) in cultured endothelial cells.

[1]Endothelium. 2008 May-Jun; 15(3): 127-36
Kusano K, Thomas TN, Fujiwara K

Protein-zero related (PZR) is an immunoglobulin V (IgV)-type immunoreceptor with two immunoreceptor tyrosine-based inhibitory motifs (ITIMs). PZR interacts with Src homology 2 domain-containing tyrosine phosphatase (SHP-2) via its tyrosine-phosphorylated ITIMs, for which c-Src is a putative kinase. Towards elucidating PZR function in endothelial cells (ECs), the authors cloned PZR from bovine aortic endothelial cells (BAECs) and characterized it. Mature bovine PZR had 94.8% and 92.7% sequence identity with canine and human proteins, respectively, and the two ITIM sequences were conserved among higher vertebrates. PZR was expressed in many cell types and was localized to cell contacts and intracellular granules in BAECs and mesothelioma (REN) cells. Coimmunoprecipitation revealed that PZR, Grb-2-associated binder-1 (Gab1), and platelet endothelial cell adhesion molecule-1 (PECAM-1) were three major SHP-2-binding proteins in BAECs. H(2)O(2) enhanced PZR tyrosine phosphorylation and PZR/SHP-2 interaction in ECs in a dose-and time-dependent manner. To see if tyrosine kinases other than Src are also capable of phosphorylating PZR, the authors cotransfected HEK293 cells with PZR and one of several tyrosine kinases and found that c-Src, c-Fyn, c-Lyn, Csk, and c-Abl, but not c-Fes, phosphorylated PZR and increased PZR/SHP-2 interaction. These results suggest that PZR is a cell adhesion protein that may be involved in SHP-2-dependent signaling at interendothelial cell contacts.



___
Source: http://www.hubmed.org/display.cgi?uids=18568953
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Nevada woman awarded millions in damages against Wyeth dies at 65



---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Nevada woman awarded millions in damages against Wyeth dies at 65
To: mesothelioma77@gmail.com


According to her lawyer, Pamela Forrester of Yerington was under hospice care for lung cancer before she died Thursday.

Sat, 21 Jun 2008 21:32:24 GMT


Source: http://www.ktnv.com/Global/story.asp?S=8535609
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc


Fwd: Personalized medicine initiative targets lung cancer (PhysOrg)



---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Personalized medicine initiative targets lung cancer (PhysOrg)
To: mesothelioma77@gmail.com


A U.S.-based personalized medicine initiative led by scientists from the Biodesign Institute, Translational Genomics Research Institute (TGen) and Seattle`s Fred Hutchinson Cancer Research Center has secured its first major international collaboration with the government of Luxembourg.

Fri, 20 Jun 2008 18:57:59 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11d4d26ed/*http%3A//www.physorg.com/news133192168.html
--
 ~
 

 

Fwd: Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.
To: mesothelioma77@gmail.com


[1]Clin Exp Metastasis. 2008 Jun 20;
Metge BJ, Frost AR, King JA, Dyess DL, Welch DR, Samant RS, Shevde LA

Breast Cancer Metastasis Suppressor 1 (BRMS1) suppresses metastasis of human breast cancer, ovarian cancer and melanoma in athymic mice. Studies have also shown that BRMS1 is significantly downregulated in some breast tumors, especially in metastatic disease. However, the mechanisms which regulate BRMS1 expression are currently unknown. Upon examination of the BRMS1 promoter region by methylation specific PCR (MSP) analysis, we discovered a CpG island (-3477 to -2214), which was found to be hypermethylated across breast cancer cell lines. A panel of 20 patient samples analyzed showed that 45% of the primary tumors and 60% of the matched lymph node metastases, displayed hypermethylation of BRMS1 promoter. Furthermore, we found a direct correlation between the methylation status of the BRMS1 promoter in the DNA isolated from tissues, with the loss of BRMS1 expression assessed by immunohistochemistry. There are several studies investigating the mechanism by which BRMS1 suppresses metastasis; however thus far there is no study that reports the cause(s) of loss of BRMS1 expression in aggressive breast cancer. Here we report for the first time that BRMS1 is a novel target of epigenetic silencing; and aberrant methylation in the BRMS1 promoter may serve as a cause of loss of its expression.



___
Source: http://www.hubmed.org/display.cgi?uids=18566899
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Breast cancer screening in France: results of the EDIFICE survey.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Breast cancer screening in France: results of the EDIFICE survey.
To: mesothelioma77@gmail.com


[1]Int J Med Sci. 2008; 5(3): 106-12
Pivot X, Rixe O, Morere J, Coscas Y, Cals L, Namer M, Serin D, Dolbeault S, Eisinger F, Roussel C, Blay J

BACKGROUND: The EDIFICE survey aimed to investigate the compliance of the general population to the screening tests available in France for the 4 most common cancers: breast, colorectal, prostate and lung. Implementation of breast cancer screening has been generalized in France since 2003: women aged between 50 and 74 years are systematically invited to perform a mammography every second year. Results pertaining to breast cancer are reported hereafter. METHODS: This nationwide observational survey was carried out in France from 18 January to 2 February 2005 among representative samples of 773 women aged between 40 and 75 years and 600 general practitioners (GPs). Information collected included socio-demographic characteristics, attitude towards cancer screening and actual experience of cancer screening, as well as GPs' practice regarding screening. The precision of the results is +/- 4.3% for a 95% confidence interval. RESULTS: Among the 507 participating women aged between 50 and 74 years, 92.5% (469/507) had undergone at least one mammography: 54.6% (256/469) underwent this test on their own initiative and 44.6% (209/469) of women performed it in the framework of a systematic screening plan. Most women participating in the systematic screening (89.0% i.e. 186/209) had a mammography within the last dating from less than 2 years versus 73.8% (189/256) of those who performed it outside the screening program (Chi(2) test; p

___
Source: http://www.hubmed.org/display.cgi?uids=18566655
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Genes controlling spread of breast cancer to lung "gang of 4".



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Genes controlling spread of breast cancer to lung "gang of 4".
To: mesothelioma77@gmail.com


[1]Exp Oncol. 2008 Jun; 30(2): 91-5
Eltarhouny SA, Elsawy WH, Radpour R, Hahn S, Holzgreve W, Zhong XY

Cancer-related mortality is caused in a large part by the metastasis of primary tumor. Each cancer has a particular way of spreading cancerous cells. Recently, genetic and pharmacological analysis identified the set of genes, such as epidermal growth factor receptor ligand epiregulin (EREG), cyclooxygenase-2 (COX2) and matrix metalloproteinases 1 and 2 (MMP-1 and MMP-2) that have been found to be associated with metastasis of breast cancer to lung. Inhibition of EGFR and COX2 could minimize lung metastasis of breast cancer in a clinical setting. In this review, we summarized the current knowledge on EREG, COX2, MMP-1 and MMP-2 in tumor development and metastasis.



___
Source: http://www.hubmed.org/display.cgi?uids=18566569
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc